Psoriatic patients are associated with increased risk of developing metabolic syndrome: An institution based case control study
Psoriasis and metabolic syndrome
DOI:
https://doi.org/10.66344/jpad.v33i3.2273Keywords:
Psoriasis, Metabolic syndrome, PASI scoreAbstract
Objective This study aimed to find out the association of metabolic syndrome, risk factors, individual components of metabolic syndrome and the other related parameters in patients with psoriasis and compare it with non-psoriatic patients.
Methods Institution based case control study including 101 patients of psoriasis and 90 controls. Data analysis statistically done by using t-test/ ANOVA test or chi square/ Fischer’s test.
Results In this study, we found strong correlation between types of psoriasis (plaque type 76.47% followed by erythrodermic type 14.71% of psoriatic patients with metabolic syndrome) and metabolic syndrome while no such association found with severity of psoriasis (PASI score), different demographic parameters with metabolic syndrome in both the groups. At the same time smoking and alcohol consumption were found to be significant risk factors for developing metabolic syndrome.
Conclusion In our study, there is a significantly higher prevalence of metabolic syndrome in patients with psoriasis comparing to non psoriatic population while it failed to show any significant association between psoriasis and dyslipidemia.
References
1. Schon MP, Boehncke WH. Psoriasis. N Engl J Med. 2005;352:1899-912.
2. Gelfand JM, Weinstein R, Porter SB, Neimann AL, Berlin JA, Margolis DJ. Prevalence and treatment of psoriasis in the United Kingdom: A population-based study. Arch Dermatol. 2005;141:1537-41.
3. Dogra S, Yadav S. Psoriasis in India: Prevalence and pattern. Indian J Dermatol Venereol Leprol. 2010;76:595-601.
4. 4.Lima Ede A, Lima Mde A. Reviewing concepts in the immunopathogenesis of psoriasis. An Bras Dermatol. 2011;86:1151-8.
5. Reich K. The concept of psoriasis as a systemic inflammation: implications for disease management. J Eur Acad Dermatol Venereol. 2012;26:3-11.
6. Henseler T, Christophers E. Disease concomitance in psoriasis. J Am Acad Dermatol. 1995;32:982–6.
7. Sommer DM, Jenisch S, Suchan M, Christophers E, Weichenthal M. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res. 2006;298(7):321–8.
8. Takahashi H, Iizuka H. Psoriasis and metabolic syndrome. J Dermatol. 2012;39:212-8.
9. Vettor R, Milan G, Rossato M, Federspil G. Review article: adipocytokines and insulin resistance. Aliment Pharmacol Ther. 2005;22:3–10. 99
10. Correia ML, Rahmouni K. Role of leptin in the cardiovascular and endocrine complications of metabolic syndrome. Diabetes Obes Metab. 2006;8:603–10.
11. Iwashima Y, Katsuya T, Ishikawa K, Ouchi N, Ohishi M, Sugimoto K et al. Hypoadiponectinemia is an independent risk factor for hypertension. Hypertension. 2004;43:1318–23.
12. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Ecke RH, Franklin BA et al. Diagnosis and Management of the Metabolic Syndrome. Circulation. 2005;112:2735-52.
13. Eckel RH. The Metabolic Syndrome. In: Longo DL, Kasper DL, Jameson JL, Fauci AS, Hauser SL, Loscalzo, editors. Harrison's Principles of Internal Medicine. 18th ed. New York: McGraw-Hill; 2012. p.1992-7.
14. Expert panel on detection,evaluation, and treatment of high blood cholesterol in adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;285:2486-97.
15. Parikh RM, Mohan V. Changing definitions of metabolic syndrome. Indian J Endocr Metab. 2012;16:7-12.
16. Nisa N, Qazi MA. Prevalence of metabolic syndrome in patients with psoriasis. Indian J Dermatol Venereol Leprol. 2010;76:662-5.
17. Gisondi P, Tessari G, Conti A, Piaserico S, Schianchi S, Peserico A et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol. 2007;157:68-73.
18. Kim GW, Park HJ, Kim HS, Kim SH, Ko HC, Kim BS et al. Analysis of cardiovascular risk factors and metabolic syndrome in korean patients with psoriasis. Ann Dermatol. 2012;24:11-5.
19. Zindancı I, Albayrak O, Kavala M, Kocaturk E, Can B, Sudogan S et al. Prevalence of metabolic syndrome in patients with psoriasis. Sci World J. 2012;2012:312463.
20. Madanagobalane S, Anandan S. Prevalence of metabolic syndrome in south Indian patients with psoriasis vulgaris and the relation between disease severity and metabolic syndrome: A hospital-based case-control study. Indian J Dermatol. 2012;57:353-7
21. Chen YJ, Wu CY, Shen JL, Chu SY, Chen CK, Chang YT et al. Psoriasis independently associated with hyperleptinemia contributing to metabolic syndrome. Arch Dermatol. 2008;144:1571-5.
22. Pereira RR, Amladi ST, Varthakavi PK. A study of the prevalence of diabetes, insulin resistance, lipid abnormalities, and cardiovascular risk factors in patients with chronic plaque psoriasis. Indian J Dermatol. 2011;56:520-6.
23. Herron MD, Hinckley M, Hoffman MS, Papenfuss J, Hansen CB, Callis KP et al. Impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol. 2005;141:1527-34.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Ashim Kumar Mondal, Debabrata Bandyopadhyay, Nilay Kanti Das, Rajarajan Thangaraj, Anupam Roy
This work is licensed under a Creative Commons Attribution 4.0 International License.
Submission declaration
Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.
